Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02199743 · ClinicalTrials.gov registry record · Phase 4
Lurasidone Effects on Tissue Glutamate in Schizophrenia
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT02199743 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 35 participants.
The verdict
NCT02199743, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.
Interventions
- DRUG Haloperidol
- DRUG Lurasidone
- DRUG Perphenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02199743
The ClinicalTrials.gov registry entry for NCT02199743 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Haloperidol is the first listed.
NCT02199743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02199743 about?
NCT02199743 is a clinical study titled "Lurasidone Effects on Tissue Glutamate in Schizophrenia". 24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidon...
What is the current status of trial NCT02199743?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2013-02. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02199743?
The interventions under investigation include: Haloperidol (DRUG), Lurasidone (DRUG), Perphenazine (DRUG).
Who is sponsoring clinical trial NCT02199743?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.